Want to create an interactive transcript for this episode?
Podcast: Tech Talks
Episode: In The Middle Of The Ozempic Gold Rush Habitual Refused the âEasyâ Revenue: We Find Out Why
Description: GLP-1 medications like Ozempic and Mounjaro have changed the world, but they aren't a silver bullet. Napala Pratini, co-founder of Habitual, joins David to discuss the âhard stuffâ behind the hype: behavior change, side effects, and the ethics of digital health. She reveals why her company turned down the chance to just âstack drugs high and sell them cheapâ and opens up about the isolation of the âtoxic founder cult.âWhatsApp us on +447392087344Â Want to read the latest from David, his Substack (diving into âTech Talksâ and more) is here.Tech Talks i...